Yan Tereshko, Simone Dal Bello, Sara Pez, Enrico Belgrado, Christian Lettieri, Bruno Hector Ercole, Giulia Cellante, Caterina Del Regno, Giuseppe Sportelli, Giovanni Ermanis, Salvatore Versace, Giovanni Merlino, Gian Luigi Gigli, Mariarosaria Valente
Background: Few studies compare the clinical effectiveness of the three anti-CGRP mAbs. Moreover, no studies compare their efficacy during suspension and reprisal. Our study aimed to compare the efficacy of migraine frequency, intensity, and symptomatic medication intake during the first year of therapy, a 1-month suspension period, and a 3-month drug reprisal. Methods: A total of 160 migraineurs (chronic and high-frequency episodic) were treated with anti-CGRP mAbs (49 with fremanezumab, 55 with erenumab, and 55 with galcanezumab) for 12 months...
November 26, 2023: Journal of Clinical Medicine